• Login
    View Item 
    •   Home
    • Nottinghamshire Healthcare NHS Foundation Trust
    • Conditions and Diseases
    • Mental Health and Behavioural Conditions
    • Psychosis and Schizophrenia
    • View Item
    •   Home
    • Nottinghamshire Healthcare NHS Foundation Trust
    • Conditions and Diseases
    • Mental Health and Behavioural Conditions
    • Psychosis and Schizophrenia
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of EMERCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjectsProfilesView

    My Account

    LoginRegister

    Links

    About EMERPoliciesDerbyshire Community Health Services NHS Foundation TrustLeicester Partnership TrustNHS Nottingham and Nottinghamshire CCGNottinghamshire Healthcare NHS Foundation TrustNottingham University Hospitals NHS TrustSherwood Forest Hospitals NHS Foundation TrustUniversity Hospitals of Derby and Burton NHS Foundation TrustUniversity Hospitals Of Leicester NHS TrustOther Resources

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Audit on clozapine dose and plasma level correlation for patients with chronic treatment-resistant psychosis

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Macnamara, Olivia
    Lawton, John D.
    Lankappa, Sudheer
    Keyword
    Psychosis
    Treatment adherence and compliance
    Antipsychotic agents
    Clinical audit
    Date
    2021
    
    Metadata
    Show full item record
    DOI
    10.1192/bjo.2021.273
    Publisher's URL
    https://www.cambridge.org/core/journals/bjpsych-open/article/audit-on-clozapine-dose-and-plasma-level-correlation-for-patients-with-chronic-treatmentresistant-psychosis/DD32352630E5A8A8B2E44A5E2629CC9F
    Abstract
    Aims Clozapine is associated with a risk of severe adverse events for which there are current monitoring systems are in place; however, there are no established regimens for monitoring of clozapine plasma levels. Recent Medicines and Healthcare products Regulatory Agency (MHRA) guidance advises clozapine levels should be monitored in certain clinical situations where toxicity may be suspected. This audit aimed to evaluate current practice of clozapine level monitoring within one Local Mental Health Team (LMHT). Method Electronic (RiO) records of 41 patients (33 male, 8 female; aged from 27 to 76 years; mean age 45 years) registered to the ZTAS system within the Nottingham City Central LMHT were reviewed. 46% had been on clozapine for over 16 years. 73.3% of patients were within clusters 12 and 13; 25.4% of patients were in cluster 11, with one patient in cluster 8. Dates of clozapine plasma level tests for each patient between 2006 and 2020 were found on the electronic NoTIS system, along with clozapine, norclozapine and total clozapine levels. Concurrent clozapine dose and regimens were obtained from pharmacy records from 2018 onwards. Result 273 clozapine plasma levels were conducted between 2006 and 2020. The average interval between levels taken was 10 months, 2 weeks but had a wide range, the shortest interval being 2 days, the longest being 13 years. 88 levels taken were >600 ug/L, suggesting increased toxicity risk. 108 levels were <350 ug/L, suggesting possible sub-optimal dosing or non-compliance. Statistical tests on correlation coefficient, although statistically non-significant (R = 0.37), showed a positive trend between total clozapine dose and the plasma level between all 3 parameters (i.e. clozapine, norclozapine and total clozapine). Conclusion There does not appear to be any routine plasma clozapine level monitoring throughout the LMHT with an average interval between tests of 10 months. There was a non-significant but positive trend between total daily dose of clozapine and clozapine level. 32% of clozapine levels returned were higher than the recommended level. We would recommend as suggested in the guidelines from MHRA, clozapine plasma levels should be monitored in certain clinical situations with increased toxicity risk. Trough levels should be taken with records of time of previous dose taken. Limitations of this study included a small sample size (41 patients) with data collection reliant on electronic systems. It was unclear if these results represent trough levels, making values difficult to interpret. Multifactorial impact on clozapine metabolism causes wide patient variability in plasma levels.
    Citation
    Macnamara, O., Lawton, J. D. & Lankappa, S. (2021). Audit on clozapine dose and plasma level correlation for patients with chronic treatment-resistant psychosis. In: Kaufman, K., (Ed.) RCPsych International Congress 2021, 21-24 June 2021 Virtual. London, England: BJPsych Open, p.S90-S90.
    Type
    Conference Proceeding
    URI
    http://hdl.handle.net/20.500.12904/14870
    Collections
    Psychosis and Schizophrenia
    Medicines Management

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.